Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Gains Medicis Through $2.6 Billion Acquisition

This article was originally published in The Gray Sheet

Executive Summary

The deal is mostly pharmaceutical focused, but Medicis sells several injectable dermal filler devices, including Restylane and Perlane.

You may also be interested in...

Nestlé/Galderma Expands U.S. Dermal-Filler Stake As Valeant Raises Bid For Allergan

Swiss dermatology firm Galderma, soon to be a Nestlé subsidiary, will gain access to the Sculptra dermal filler device and a North American sales presence for four other medical aesthetics products in a $1.4 billion sell-off by Valeant intended to strengthen its position to buy Allergan.

Deals Of The Week: Can Endo Succeed By Copying The Valeant Model?

NuPathe and its migraine patch product Zecuity are the latest acquisition by Endo since former Valeant executive Rajiv De Silva moved into the chief executive’s office – will he succeed in bringing his former company’s model to the specialty firm? Plus, Valeant made its own news during the week, while AstraZeneca bought out Bristol’s share of their diabetes joint venture, and more.

Valeant Adds Energy To Its Aesthetics Offerings With Solta Medical

Valeant Pharmaceuticals says it will buy energy-based aesthetics device firm Solta Medical for about $250 million, to expand the breadth of its offerings to dermatologists and plastic surgeons.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts